CAR T-cell therapy is a revolutionary blood cancer treatment that helps the body combat tumors using its own T-cells. The therapy involves collecting the patient’s blood, separating T-cells, and genetically engineering them to produce chimeric antigen receptors (CARs). These allow the T-cells to recognize tumor cells, targeting and destroying them. After their alteration, T-cells are multiplied in a laboratory and then reintroduced to the patient’s body.
CAR T-cell therapy is a cutting-edge treatment available only at a limited number of cancer centers worldwide. At Sheba, CAR T-cell therapy has been offered since 2015, with over 220 patients who have undergone the therapy since.
Until recently, Sheba offered CAR T-cell therapy for acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. Following recent FDA approval, we are pleased to announce that CAR T-cell therapy is now available for the treatment of multiple myeloma patients.
By choosing Sheba for treatment, multiple myeloma patients can benefit from the experience of world-renowned specialists, including Prof. Arnon Nagler, President of the Hemato-Oncology Center, as well as end-to-end treatment in one facility.
Commenting on the addition of CAR T-cell therapy to the multiple myeloma therapeutic arsenal, Director of the Multiple Myeloma Unit at Sheba, Dr. Hila Magen, explained: “We are talking about an advanced immunotherapy that ‘re-educates’ the patient’s immune system to fight cancerous myeloma cells. It is truly an incredible breakthrough that opens the door for new multiple myeloma therapeutic approaches.”
